News | April 28, 2023
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Bridging the gap between histopathology and molecular pathology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Apollo continues to invest in genomics technology and research for better patient care
Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Subscribe To Our Newsletter & Stay Updated
